



[www.emvision.com.au](http://www.emvision.com.au)

# AGM 2023 CEO PRESENTATION



NOVEMBER 2023

ASX:EMV

# DISCLAIMER

This presentation has been prepared by EMVision Medical Devices Limited (“EMVision” or “the Company”). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in EMVision in any jurisdiction. This presentation contains general information only and does not consider the investment objectives, financial situation and needs of individual investors.

Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser having regard to their personal objectives, financial situation and needs before taking any action. No representation or warranty, express or implied, is made as to the accuracy, completeness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty (express or implied) given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or returns contained in this presentation. Similarly, past performance, including information concerning historical cash burn rates, should not be seen as indicative of future performance.






Such forecasts, prospective statements or returns are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of EMVision. To the maximum extent permitted by law, EMVision and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation.

An investment in EMVision securities should be considered speculative and is subject to investment and other known and unknown risks, some of which are beyond the control of EMVision. EMVision does not guarantee any rate of return or the absolute or relative investment performance of EMVision securities. The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions.

# MEET THE TEAM

## SIGNIFICANT MEDICAL DEVICE DEVELOPMENT AND GLOBAL COMMERCIALISATION EXPERTISE ACROSS THE GROUP

### EXECUTIVE LEADERSHIP TEAM

	<b>Scott Kirkland</b> CEO and Managing Director Co-founder	Sales and marketing executive, former Head of Client Sales at US-venture backed global AI advertising company Quantcast.
	<b>Forough Khandan</b> Chief Technology Officer	Over 15 years medical device development expertise. Former Head of Program Management Nanosonics (ASX:NAN), a \$1.3bn medical device success story.
	<b>Professor Stuart Crozier</b> Chief Scientific Officer Co-inventor	Pioneer in medical imaging innovation. Prof Crozier's advancements in MRI technology now central to 65% of all MRI machines.
	<b>Robert Tiller</b> Head of Design	Over 25 years in medical device product design and commercialization, previously CEO of Tiller Design.
	<b>Dr. Christian Wight</b> Head of Regulatory Affairs	Previously Regulatory Manager at Corin. Multiple successful FDA, CE and TGA registrations.
	<b>Emma Waldon</b> CFO, Company Secretary	20+ years corporate advisory, capital market and cooperate governance experience in Australia and UK.

### BOARD OF DIRECTORS

	<b>John Keep</b> Independent Non-Executive Chairman	As former CEO of Queensland Diagnostic Imaging, John grew the business to become one of the state's leading private imaging group and led the successful trade sale of the group.
	<b>Dr Ron Weinberger</b> Strategic advisor, Non-Executive Director	Former Executive Director and CEO of Nanosonics (ASX:NAN). Former CEO of EMVision. Over 20-years' experience developing and commercializing medical devices.
	<b>Dr Philip Dubois</b> Independent Non-Executive Director	Neuroradiologist, former CEO of Sonic Healthcare Imaging (ASX:SHL), \$14bn market cap. Currently an Associate Professor of Radiology at the University of Queensland Medical School. Has served on numerous government and radiology group bodies.
	<b>Tony Keane</b> Independent Non-Executive Director	Non-executive Chairman of National Storage Holdings Ltd (ASX:NSR), \$3bn market cap. Previously held numerous roles with a major trading bank principally in business, corporate and institutional banking.
	<b>Geoff Pocock</b> Independent Non-Executive Director	Over 20 years' experience in commercialisation, corporate finance. Chairman of Argenica Therapeutics (ASX:AGN).

# OUR VISION IS TO REDUCE THE GLOBAL BURDEN OF STROKE AND OTHER TIME SENSITIVE MEDICAL EMERGENCIES

## FIRST INDICATION - STROKE

- 1 in 4 adults will have a stroke in their lifetime
- 2 out of 3 strokes result in permanent disability
- 34% of total global healthcare expenditure is spent on stroke
- The average healthcare cost of stroke per person in the United States is USD \$140,048

Every 10 minutes can SAVE up to 20 MILLION brain cells



## SECOND INDICATION - TRAUMATIC BRAIN INJURY (TBI)

- An estimated 50-60 million people, worldwide, will suffer a TBI this year.
- Those TBIs each year are estimated to cost the world economy upwards of \$US400 billion
- One of the most common severe types of TBI is acute subdural hematoma, caused by rupture of blood vessels
- For patients with suspected traumatic brain injuries, quick evaluation is critical
- Most patients with suspected traumatic brain injury are examined using a neurological scale (GCS) which is imprecise and can lead to biases in care (Matney C 2022).

## EMVISION'S PORTFOLIO OF WORLD FIRST POINT-OF- CARE BRAIN SCANNERS IS THE SOLUTION

Neuroimaging as is  
accessible today.

- Large
- Expensive
- For most part stationary
- Ionizing radiation (CT) and ferromagnetism (MRI)
- Requires special infrastructure
- Requires specialist operators



1st Gen (Bedside)

EMVision,  
Neuroimaging  
anywhere.

- ✓ Portable, compact
- ✓ Cost effective
- ✓ Non-invasive
- ✓ Faster diagnosis, faster treatment
- ✓ Better monitoring
- ✓ Less disability
- ✓ Improved quality of life
- ✓ Significant healthcare & insurer savings



2nd Gen (First responder)



# 2023 HIGHLIGHTS



1<sup>st</sup> Gen bedside scanner undergoing multi-site clinical trials at leading comprehensive stroke centers; Liverpool Hospital, Royal Melbourne and Princess Alexandra, with significant positive progress achieved.




Encouraging interim algorithm testing for 'Blood or not' classification capabilities, to answer one of the key clinical questions in acute stroke care.



Advanced first responder (Gen 2) prototype assembled for bench testing and subsequent healthy volunteer testing in lead up to 'proof of concept' build.



\$6.05m in non-dilutive grant funds received thus far in 2023 to support product development, clinical testing and the commercialization pathway.



Initial round of testing with a new AI-powered probabilistic anatomical imaging technique on volunteers completed with improved fidelity over earlier anatomical imaging techniques.



IP portfolio has grown to approximately 14 patent families covering methods of acquisition, imaging reconstruction techniques and calibration alongside several trade secrets.




Early clinical trial insights published in International Journal of Stroke alongside presentation at the Stroke Society of Australasia.



EMVision was named the top innovator in the Health category in the 2023 AFR BOSS Most Innovative Companies List.

# HOW EMVISION'S IMAGING COMES TOGETHER

EMVision is developing a “zero to one” medical imaging technology with a series of algorithms that are combined to help answer important clinical questions in acute stroke care:




*Probabilistic anatomical reconstruction is intended as a fiducial and orientation tool.  
Algorithms are subject to further development, verification and validation.*


# LATEST PATIENT IMAGING CASE STUDIES

In these examples from EMVision's multi-site clinical trials (pre-validation phase), the EMVision algorithms are able to detect, correctly localize by quadrant ('heatmap' of greatest intensity) and classify intracerebral hemorrhage ('blood or not') and other ('no blood') cases.

Case study A – Intracerebral Hemorrhage (ICH volume ~13.8 mL)




Case study B – Intracerebral Hemorrhage (ICH volume ~4.7 mL)




EMVision  
Model output

Ground truth  
Non-contrast CT

Case study C – Healthy volunteer



Case study D – Mimic (migraine)



EMVision  
Model output

Ground truth  
MRI (top) CT (bottom)

*These 'development in progress' algorithm case studies of patients with intracerebral hemorrhage and other participants are subject to further development, verification and validation. The ground truth 'CT' and 'MRI' slices are an approximate reference point to the EMV scan acquisition, and not the identical plane.*




# PATHWAY TO MARKET ENTRY (GEN 1 DURING FY25)


## GEN 1




BEDSIDE



## GEN 2



FIRST RESPONDER



\*See ASX “Latest imaging and clinical trial insights” released 22nd August 2023 for further information on clinical investigations roadmap  
The indicative studies roadmap and timetable is a guide of EMVision’s intentions at the date of this presentation only. EMVision reserves the right to vary this plan and timetable at its discretion, and further notes the above timings are subject to change due to circumstances outside of its control.

# SET UP FOR SUCCESS

- ✓ We have assembled a team of medtech experts that have successfully done this before and created significant shareholder value
- ✓ We have compelling support from the leading minds in stroke care
- ✓ Multi-billion-dollar market opportunity in stroke care alone
- ✓ Globally there is an increasing demand for point-of-care imaging solutions
- ✓ Our technology has additional applications for unmet clinical needs of high value, including traumatic brain injury
- ✓ Our multiple non-dilutive funding sources provide strong endorsement and offer flexibility to accelerate the commercialization of our product portfolio



## KEY UPCOMING CATALYSTS



Generate pre-validation and validation clinical trial data, achieving endpoints and recruitment objectives. Anticipated stage 2 reporting CY Q1 2024. FDA engagement.



Establish commercial partnership/s & strategic relationships



Gen 2 Advanced Prototype bench testing underway & healthy volunteer studies coming months, Gen 2 proof of concept unit build and road & air trials (during CY2024)



Establishment of commercial manufacturing



Regulatory submissions and approvals